Medical Device Combines Nanotechnology to Diagnose Kidney Disease
|
By LabMedica International staff writers Posted on 17 Mar 2015 |

Image: The quantitative electrochemical lateral flow assay (QELFA) device (Photo courtesy of Somersault 18:24).
A new medical device which combines nanotechnology with a pregnancy tester could help diagnose and treat the one million people in the UK who don't know they have kidney disease.
Every day 19 people in the UK are diagnosed with kidney failure yet there is currently no device that can be used by doctors for day-to-day monitoring of kidney disease and four of the 19 people will not have visited specialist services for sufficient time to prepare for their treatment.
The apparatus is a quantitative electrochemical lateral flow assay (QELFA) and uses nanoparticles to test the patient's urine giving results in seconds. It is linked via mobile technology so doctors can track how the disease is developing. The devise was developed by engineers and costs about GBP 10 can be used at home and could revolutionize kidney disease care in the UK, which currently costs the UK National Health Service (NHS) over GBP 1.4 billion, more than breast, lung, colon and skin cancer combined.
The devise which works like a pregnancy test was created by Bio Nano Consulting (London, UK). The digital readout of the test enables the automatic and accurate collation of kidney-function readings into a central database using mobile technology. Behind the patients who develop kidney failure and in need of rapid diagnosis are many more who will have a lesser degree of kidney dysfunction, called Chronic Kidney Disease (CKD), that will place them at increased risk of cardiovascular disease and acute kidney injury.
Helen Meese CEng, MIMech, PhD, Head of Materials at the Institution of Mechanical Engineers (London, UK), said, “The QELFA device is a brilliant example of what's possible. Using an old technology like a pregnancy tester and combining it with nanotechnology, you have a device which could not only diagnose the million people in the UK who are unaware they have kidney disease, but also help doctors effectively monitor those undergoing treatment. It could also save the NHS millions of pounds a year. But although the UK has been at the forefront of nanotechnology development, we still lag behind in its commercialization and many people are still unsure of its potential. We must change this.”
Related Links:
Bio Nano Consulting
Institution of Mechanical Engineers
Every day 19 people in the UK are diagnosed with kidney failure yet there is currently no device that can be used by doctors for day-to-day monitoring of kidney disease and four of the 19 people will not have visited specialist services for sufficient time to prepare for their treatment.
The apparatus is a quantitative electrochemical lateral flow assay (QELFA) and uses nanoparticles to test the patient's urine giving results in seconds. It is linked via mobile technology so doctors can track how the disease is developing. The devise was developed by engineers and costs about GBP 10 can be used at home and could revolutionize kidney disease care in the UK, which currently costs the UK National Health Service (NHS) over GBP 1.4 billion, more than breast, lung, colon and skin cancer combined.
The devise which works like a pregnancy test was created by Bio Nano Consulting (London, UK). The digital readout of the test enables the automatic and accurate collation of kidney-function readings into a central database using mobile technology. Behind the patients who develop kidney failure and in need of rapid diagnosis are many more who will have a lesser degree of kidney dysfunction, called Chronic Kidney Disease (CKD), that will place them at increased risk of cardiovascular disease and acute kidney injury.
Helen Meese CEng, MIMech, PhD, Head of Materials at the Institution of Mechanical Engineers (London, UK), said, “The QELFA device is a brilliant example of what's possible. Using an old technology like a pregnancy tester and combining it with nanotechnology, you have a device which could not only diagnose the million people in the UK who are unaware they have kidney disease, but also help doctors effectively monitor those undergoing treatment. It could also save the NHS millions of pounds a year. But although the UK has been at the forefront of nanotechnology development, we still lag behind in its commercialization and many people are still unsure of its potential. We must change this.”
Related Links:
Bio Nano Consulting
Institution of Mechanical Engineers
Latest Technology News
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
Channels
Clinical Chemistry
view channel
International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
Interpreting serum calcium can be clinically challenging when albumin levels vary, especially in patients with chronic illness or kidney disease. For decades, laboratories have used formulas to adjust... Read more
Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
Prostate cancer is among the most common cancers in men, and the role of population screening has remained controversial because of overdiagnosis and overtreatment. Health systems have sought clearer,... Read moreMolecular Diagnostics
view channel
Expanded DPYD Genotyping Test Supports Safer Chemotherapy Dosing
Fluoropyrimidines such as 5-fluorouracil (5-FU) are chemotherapy drugs prescribed to more than two million cancer patients each year, but 10–20% of patients can experience severe, and sometimes fatal,... Read more
Multi-Omics Profiling Helps Predict BCG Response and Recurrence in Bladder Cancer
High-risk non–muscle-invasive bladder cancer frequently recurs after therapy, with about 30% of patients relapsing and roughly 10% dying within two years despite tumor resection, surveillance, and Bacillus... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read more
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read moreMicrobiology
view channel
Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read morePathology
view channel
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more
AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read moreIndustry
view channel
Partnership Brings Single-Cell Analysis into Clinical Oncology Workflows
Selecting treatments for advanced cancer remains difficult when bulk analyses mask the functional diversity of tumor cells and mechanisms of resistance that emerge over time. Clinicians increasingly need... Read more








